Influence of Metoprolol Treatment on Sympatho-Adrenal Activation of Fibrinolysis

Summary

The effects of mental stress (a colour word conflict test, CWT) and adrenaline infusions (0.1 and 0.4 nmol kg⁻¹ min⁻¹) on t-PA activity, t-PA antigen, PAI-1 activity and PAI-1 antigen were studied in 18 healthy male volunteers. Furthermore, the effects of metoprolol (200 mg/day during 1 week) or placebo (double-blind cross-over study) on fibrinolytic responses to sympatho-adrenal activation, and relationships between fibrinolysis and blood lipids were investigated.

Low and high dose adrenaline infusions yielding plasma adrenaline levels of 0.9 ± 0.1 and 3.4 ± 0.4 nmol/1, respectively, dose-dependently increased t-PA levels with a concomitant decrease in PAI-1 levels. A similar, but weaker, fibrinolytic response seemed to occur during CWT when plasma adrenaline levels were only moderately increased (to 0.4 ± 0.1 nmol/1). Metoprolol treatment did not influence the resting levels of the fibrinolytic variables studied, but tended to enhance the t-PA response to CWT and further reduce PAI-1 during adrenaline infusion. Metoprolol treatment was not accompanied by any rise in PAI-1 levels despite drug induced elevations of triglyceride levels. Thus, the present study shows that sympatho-adrenal activation increases fibrinolytic activity in vivo and that meto prolol treatment may have a favourable influence on this activity.

• References

• 1 Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-63
• 2 Prowse CV, Cash JD. Physiologic and pharmacologic enhancement of fibrinolysis. Semin Thromb Hemostas 1984; 10: 51-60
• 3 Gader AM A, Clarkson AR, Cash JD. The plasminogen activator and coagulation factor VIII responses to adrenaline, noradrenaline and salbutamol in man. Thromb Res 1973; 2: 9-16
• 4 Chmielewska J, Rånby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-36
• 5 Chmielewska J, Wiman B. Determination of tissue plasminogen activator and its “fast” inhibitor in plasma. Clin Chem 1986; 32: 482-5
• 6 Urdén G, Hamsten A, Wiman B. Comparison of plasminogen activator inhibitor activity and antigen in plasma samples. Clin Chim Acta 1987; 169: 189-96
• 7 Himms-Hagen J. Sympathetic regulation of metabolism. Pharmacol Rev 1967; 19: 367-461
• 8 Holtzman E, Rosenthal T, Goldbourt Ue, Segal P. Do Β-blockers alter lipids and what are the consequences. J Cardiovasc Pharmacol 1987; 10: S 86-92
• 9 Roberts WC. Recent studies on the effect of beta blockers on blood lipid levels. Am Heart J 1989; 117: 709-14
• 10 Aberg H, Lithell H, Selinus I, Hedstrand H. Serum triglycerides are a risk factor for myocardial infarction but not for angina pectoris. Atherosclerosis 1985; 54: 89-97
• 11 Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987; 9: 263-8
• 12 Larsson PT, Hjemdahl P, Olsson G, Egberg N, Hornstra G. Altered platelet function during mental stress and adrenaline infusions in humans: evidence for an increased in vivo aggregability as measured by filtragometry. Clin Sci 1989; 76: 369-76
• 13 Frankenhaeuser M, Mellis I, Rissler A, Bjorkvall C, Patkai P. Catecholamine excretion as related to cognitive and emotional reaction patterns. Psychosom Med 1968; 30: 109-20
• 14 Hjemdahl P. Catecholamine measurements in plasma by high-performance liquid chromatography with electrochemical detection. Methods Enzymol 1987; 142: 521-34
• 15 Henriksson P, Einarsson K, Eriksson A, Kelter U, Angelin B. Estrogen-induced gallstone disease in males. Studies on biliary lipid composition and gallstone formation during treatment of prostatic carcinoma. J Clin Invest 1989; 84: 811-6
• 16 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
• 17 Kjaelgaard A, Kjaelgaard M. In vitro stimulation of plasminogen activator release from vein walls by adrenaline. J Clin Pathol 1986; 39: 1241-4
• 18 Conanan LB, Crutchley DJ. Serum-dependent induction of plasminogen activator in human fibroblasts by catecholamines and comparison with the effects of prostaglandin E₁ . Biochim Biophvs Acta 1983; 759: 146-53
• 19 Wiman B, Chmielewska J, Rånby M. Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. J Biol Chem 1984; 259: 3644-7
• 20 Gader AM A, da Costa J, Cash JD. The effect of propranolol, alprenolol and practolol on the fibrinolytic and factor VIII responses to adrenaline and salbutamol in man. Thromb Res 1974; 4: 25-33
• 21 Teger-Nilsson AC, Dahlöf C, Haglund E, Hedman C, Olsson G, Åblad B. Influence of metoprolol on plasminogen activator inhibitor (PAI-1) in man. J Clin Pharm 1990; 30: S 132-7
• 22 Rein E, Winther K. Beta blockade, tissue plasminogen activity and exercise. Thromb Haemostas 1989; 62: 536
• 23 Grimaudo V, Hauert J, Bachmann F, Kruithof EK O. Diurnal variation of the fibrinolytic system. Thromb Haemostas 1988; 59: 495-9
• 24 Kluft C, Jie AF H, Rijken DC, Verheijen JH. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1). Thromb Haemostas 1988; 59: 329-32